Fierce Biotech regularly pulls together the industry’s top money raisers from the year before. Staff writer Gabrielle Masson and Editor-in-Chief Ayla Ellison discuss a few of the biotechs at the top of the list. 

Plus, in this episode, we cover Johnson & Johnson's talc litigation, prison plans for Elizabeth Holmes and more of this week's top headlines. 

To learn more about the topics in this episode: 
Biotech's top money raisers of 2022
Johnson & Johnson's $8.9B bankruptcy settlement is 'unworkable,' talc plaintiff lawyer says
Theranos' Elizabeth Holmes must report to prison this month despite pending appeal, judge rules
FDA dubs Abbott's FreeStyle Libre battery issues a Class I recall, spanning 4.2M devices
Philips re-recalls 1,200 CPAP, BiPAP machines repaired in far-reaching ventilator probe
Activist investor Icahn calls for Illumina CEO to be voted off company board over Grail deal
Moderna's mRNA flu shot struggles to prove its worth again in phase 3 trial
Sanofi's Provention buyout hit with FTC delay. Will Pfizer's Seagen deal go off as planned?
After last year's cuts, Biogen kicks off another round of layoffs

The Top Line is produced by senior podcast producer Teresa Carey and managing editor Querida Anderson. The sound engineer is Caleb Hodgson. The stories are by all our “Fierce” journalists. Like and subscribe wherever you listen to your podcasts.

Fierce Biotech regularly pulls together the industry’s top money raisers from the year before. Staff writer Gabrielle Masson and Editor-in-Chief Ayla Ellison discuss a few of the biotechs at the top of the list. 
Plus, in this episode, we cover Johnson &amp; Johnson's talc litigation, prison plans for Elizabeth Holmes and more of this week's top headlines. 
To learn more about the topics in this episode: 
<ul>
<li><a href="https://www.fiercebiotech.com/biotech/biotechs-top-10-money-raisers-2022">Biotech's top money raisers of 2022</a></li>
<li><a href="https://www.fiercepharma.com/pharma/johnson-johnsons-89b-bankruptcy-settlement-underhanded-talc-plaintiff-leadership-group-says">Johnson &amp; Johnson's $8.9B bankruptcy settlement is 'unworkable,' talc plaintiff lawyer says</a></li>
<li><a href="https://www.fiercebiotech.com/medtech/theranos-elizabeth-holmes-must-report-prison-later-month-despite-pending-appeal-judge-rules">Theranos' Elizabeth Holmes must report to prison this month despite pending appeal, judge rules</a></li>
<li><a href="https://www.fiercebiotech.com/medtech/fda-upgrades-abbotts-freestyle-libre-battery-issues-class-i-device-recall#:~:text=After%20Abbott%20warned%20users%20of,as%20a%20Class%20I%20recall">FDA dubs Abbott's FreeStyle Libre battery issues a Class I recall, spanning 4.2M devices</a></li>
<li><a href="https://www.fiercebiotech.com/medtech/philips-recalls-1200-cpap-bipap-machines-were-already-repaired-far-reaching-respiratory">Philips re-recalls 1,200 CPAP, BiPAP machines repaired in far-reaching ventilator probe</a></li>
<li><a href="https://www.fiercebiotech.com/medtech/activist-investor-icahn-calls-illumina-ceo-be-voted-company-board-over-grail-deal">Activist investor Icahn calls for Illumina CEO to be voted off company board over Grail deal</a></li>
<li><a href="https://www.fiercebiotech.com/biotech/modernas-mrna-flu-shot-continues-struggle-prove-its-worth-phase-3-trials">Moderna's mRNA flu shot struggles to prove its worth again in phase 3 trial</a></li>
<li><a href="https://www.fiercepharma.com/pharma/sanofis-29b-deal-provention-bio-hit-protracted-ftc-review-wheres-pfizer-seagen">Sanofi's Provention buyout hit with FTC delay. Will Pfizer's Seagen deal go off as planned?</a></li>
<li><a href="https://www.fiercepharma.com/pharma/biogens-trims-multiple-sclerosis-team-latest-layoffs-round-report">After last year's cuts, Biogen kicks off another round of layoffs</a></li>
</ul>
The Top Line is produced by senior podcast producer Teresa Carey and managing editor Querida Anderson. The sound engineer is Caleb Hodgson. The stories are by all our “Fierce” journalists. Like and subscribe wherever you listen to your podcasts.

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech, and Fierce Pharma recount the latest industry trends and why they matter. We'll analyze the week's biggest business news, from mergers and marketing to drug R&D and device development. Available every Friday morning. 

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech, and Fierce Pharma recount the latest industry trends and why they matter. We'll analyze the week's biggest business news, from mergers and marketing to drug R&amp;D and device development. Available every Friday morning.&nbsp;

The Top Line

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech and Fierce Pharma recount the latest industry trends and why they matter. We’ll analyze the week’s biggest business news—from mergers and marketing to drug R&D and device development. Available every Friday morning.

 

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech and Fierce Pharma recount the latest industry trends and why they matter. We&rsquo;ll analyze the week&rsquo;s biggest business news&mdash;from mergers and marketing to drug R&amp;D and device development. Available every Friday morning.
&nbsp;

Advertisement